Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure.

The effect of torasemide and furosemide therapy was compared in 50 patients who had chronic heart failure and symptoms [NYHA class II-III] despite long-term therapy with both low-dose furosemide and angiotensin-converting enzyme inhibitors. In this randomized 6-month, open-label trial, baseline and follow-up echocardiograms and neurohumoral assays were obtained in 25 group F patients (continued same dose of oral furosemide at 20-40 mg/day) and in 25 group T patients (received torasemide at 4-8 mg/day in place of furosemide). At 6 months, parameters were unchanged in group F whereas the group T patients had a lower left ventricular end-diastolic diameter (p<0.005) and left ventricular mass index (p<0.005) with improved Doppler filling parameters, decreased plasma B-type natriuretic concentration (p<0.001) and increased plasma concentrations of active renin (p<0.005) and aldosterone (p<0.001). The magnitude of these changes appeared dose dependent and it is suggested these favorable effects of switching from furosemide to torasemide may be related to aldosterone receptor blockade.     

托拉塞米注射液在充血性心力衰竭患者中的短期应用

目的通过对比托拉塞米与呋塞米的利尿作用，探讨托拉塞米注射液在充血性心力衰竭患者短期应用价值。方法选取充血性心力衰竭患者50例，随机分为托拉塞米组（24例）和呋塞米组（26例），在常规抗心衰治疗基础上，两组分别用托拉塞米注射液20mg／d与呋塞米注射液40mg／d治疗，连用3d。观察比较两组患者治疗前后尿量、体重、血钾的变化和不良反应。结果治疗3d后，与呋塞米组比较，托拉塞米组尿量明显增多，体重减轻明显（P均〈0．05）；托拉塞米组血钾下降较少，差异有统计学意义（P〈0．05）。结论托拉塞米注射液短期治疗充血性心力衰竭利尿效果优于呋塞米，低血钾副作用轻，不良反应少于呋塞米。     

Non-invasive measurement of cardiac output in patients with chronic heart failure

OBJECTIVES: The measurement of cardiac output by thoracic bioimpedance has been previously assessed in several studies. However, there continues to be disagreement as to whether this technique is sufficiently accurate for use in clinical practice or research. The current study aimed to compare thoracic bioimpedance (COTB) with thermodilution (COTD) in patients with stable chronic heart failure. METHODS AND RESULTS: A total of 282 paired measurements of cardiac output from 11 patients were analysed. There was good correlation between COTB and COTD (r=0.76, P<0.0001). However, Bland-Altman analysis revealed an average difference between values of 0.3 (2.2) l/min (P=0.02), suggesting a small average bias but marked variability in results. There was no significant correlation when results were expressed as percentage change from baseline and a significant average difference between values of 10.1 (30.1)%. There was no difference in between-day repeatability between thermodilution and thoracic bioimpedance [-0.2 (1.2) versus 0.1 (1.0) l/min, P=0.7]. CONCLUSIONS: This study demonstrates a correlation between the techniques but shows a poor level of agreement. The method of COTB underestimated cardiac output compared with COTD, and this difference appeared greater with higher cardiac outputs. Agreement was worse when results were expressed as change from baseline. The present study does not support the use of thoracic bioimpedance in its current form as an alternative to thermodilution in stable patients with chronic heart failure.     

Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure

BACKGROUND: Connective tissue growth factor (CTGF) has been recently reported as a mediator of myocardial fibrosis; however, the significance of plasma CTGF concentration has not been evaluated in patients with heart failure. The aim of this study was to investigate the clinical utility of plasma CTGF concentration for the diagnosis of heart failure. METHODS AND RESULTS: We evaluated fifty-two patients with chronic heart failure. The plasma concentration of CTGF and other markers of fibrosis were assessed and compared with clinical and echocardiographic data. Plasma CTGF was significantly elevated in symptomatic patients in proportion to their NYHA classes and was significantly correlated with plasma brain natriuretic peptide (BNP) concentration (r=0.395, P<0.01). Plasma CTGF was also correlated with plasma transforming growth factor beta (TGF-beta) (r=0.512, P<0.01), matrix metalloproteinase (MMP)-2 (r=0.391, P<0.05) and tissue inhibitor of MMP (TIMP)-2 (r=0.354, P<0.05) concentrations. Interestingly, plasma CTGF was correlated with E/E' value evaluated by tissue Doppler echocardiography (r=0.593, P=0.012), but not with systolic function and left ventricular mass. CONCLUSION: Our study suggests that plasma CTGF concentration is a novel diagnostic marker for cardiac dysfunction and may provide additional specific information about myocardial fibrosis in chronic heart failure patients.     

慢性心力衰竭患者心功能恢复的相关因素研究

目的:分析影响慢性心力衰竭(CHF)患者心功能恢复的相关因素。方法:连续入选232例诊断为CHF并至少随访1年的患者,记录患者临床和生化资料,并定期行超声心动图检测。Logistic回归分析评估影响CHF患者心功能恢复的相关因素。结果:232例患者中56例患者心功能恢复,176例患者心功能未恢复。扩张型心肌病患者较缺血性心肌病患者心功能更易恢复(P0.05),围生期心肌病患者预后良好。与体质量正常或过轻患者相比,体质量指数(BMI)较高的CHF患者心功能更易恢复(P0.05)。心功能恢复患者基础心率偏快,β受体阻滞剂耐受剂量较大,药物治疗后心率下降较明显(P均0.001)。Logistic回归分析显示,患者心功能恢复与CHF病因(OR=1.322,95%CI:1.256~1.392,P=0.04)和β受体阻滞剂剂量(OR=2.483,95%CI:2.359~2.614,P0.001)相关。结论:CHF病因和β受体阻滞剂剂量与CHF患者心功能恢复相关,BMI及基础心率较高患者心功能易于恢复。     

心脏再同步治疗慢性心力衰竭的建议

慢性心力衰竭是心内科治疗学上的难题，是使患者丧失工作能力，具有较高患病率和病死率的严重疾患。流行病学资料显示：美国大约有500万人罹患心力衰竭，每年新增病例55万；全球心力衰竭患病人数高达2250万，每年新增病例数200万。我国2003年一项心力衰竭流行病学调查资料显示，在35—74岁人群中，心力衰竭患病率为0．9％。按此比率推算，我国35—74岁人群中约有心力衰竭患者400万人。心力衰竭的病死率与临床严重程度相关。     

慢性心力衰竭患者心脏再同步治疗疗效观察

Objective This study was designed to evaluate the clinical outcome of cardiac resynchro-nization therapy(CRT) during short and mid-long term follow-up. Methods Consecutive patients treated with CRT between 1999 and 2008 were registered. Clinical information was collected from baseline and last follow-up. Clinical information included survival, chnical cardiac function, echocardiography parameters and QRS wave width from surface ECG. Results Ninety-five patients who were treated with CRT successfully were included. These patients were divided into two groups: those with only short term follow-up and those with mid-long term follow-up. In the short term follow-up group,survival was 89.1% with follow-up of(18±10) month(median = 18 months). Survival was 66.6% in mid-long term group with follow-up of(57±17) months (median = 54 moths). While clinical cardiac function was significantly improved in both groups the intrinsic QRS wave width did not show significant change. Those patients' medical therapy for chronic heart failure has been changed dur-ing the period of follow-up. Conclusion CRT can improve clinical cardiac function in parts of patients with chronic heart failure and increased survival during mid-long term and short term follow-up. However, there re-mains a need for more sensitive indicators.     

慢性心力衰竭患者行心脏再同步化治疗的护理

慢性心力衰竭（chronic heart failure,CHF）是一种心室功能障碍和神经内分泌调节异常导致的肺静脉充血、运动耐力和生存期降低的临床综合征,是近年来发病率和流行性很高的心血管病症。     

慢性心力衰竭患者心脏再同步治疗疗效观察

Objective This study was designed to evaluate the clinical outcome of cardiac resynchro-nization therapy(CRT) during short and mid-long term follow-up. Methods Consecutive patients treated with CRT between 1999 and 2008 were registered. Clinical information was collected from baseline and last follow-up. Clinical information included survival, chnical cardiac function, echocardiography parameters and QRS wave width from surface ECG. Results Ninety-five patients who were treated with CRT successfully were included. These patients were divided into two groups: those with only short term follow-up and those with mid-long term follow-up. In the short term follow-up group,survival was 89.1% with follow-up of(18±10) month(median = 18 months). Survival was 66.6% in mid-long term group with follow-up of(57±17) months (median = 54 moths). While clinical cardiac function was significantly improved in both groups the intrinsic QRS wave width did not show significant change. Those patients' medical therapy for chronic heart failure has been changed dur-ing the period of follow-up. Conclusion CRT can improve clinical cardiac function in parts of patients with chronic heart failure and increased survival during mid-long term and short term follow-up. However, there re-mains a need for more sensitive indicators.     

慢性心力衰竭患者心脏再同步治疗疗效观察

Objective This study was designed to evaluate the clinical outcome of cardiac resynchro-nization therapy(CRT) during short and mid-long term follow-up. Methods Consecutive patients treated with CRT between 1999 and 2008 were registered. Clinical information was collected from baseline and last follow-up. Clinical information included survival, chnical cardiac function, echocardiography parameters and QRS wave width from surface ECG. Results Ninety-five patients who were treated with CRT successfully were included. These patients were divided into two groups: those with only short term follow-up and those with mid-long term follow-up. In the short term follow-up group,survival was 89.1% with follow-up of(18±10) month(median = 18 months). Survival was 66.6% in mid-long term group with follow-up of(57±17) months (median = 54 moths). While clinical cardiac function was significantly improved in both groups the intrinsic QRS wave width did not show significant change. Those patients' medical therapy for chronic heart failure has been changed dur-ing the period of follow-up. Conclusion CRT can improve clinical cardiac function in parts of patients with chronic heart failure and increased survival during mid-long term and short term follow-up. However, there re-mains a need for more sensitive indicators.     

心脏再同步治疗除颤器治疗慢性心力衰竭的临床应用体会

目的:初步总结应用心脏再同步化治疗除颤器(CRT-D)治疗慢性心力衰竭(CHF)合并恶性室性心律失常的临床体会。方法:选取的6例CHF患者均为心功能Ⅲ～Ⅳ级(NYHA分级),且有恶性室性心律失常发作史,体表心电图QRS波0.12s,术前组织多普勒超声检查均提示存在心脏收缩不同步,药物治疗无效。置入CRT-D。随访观察患者临床症状、心功能、左室射血分数(LVEF)变化及室性心律失常的发生情况。结果:CRT-D置入术中右心房、左心室起搏电极感知和起搏参数均符合要求,右心室除颤电极的感知、起搏及除颤阈值良好。起搏前QRS时限平均189ms,起搏后平均142ms。随访6～36个月,心功能较术前明显改善,LVEF术前平均0.33,术后6个月平均0.47。6例患者随访期间共发生室性心动过速2次,CRT-D均以31～34J的能量1次除颤成功。结论:CRT-D不仅可有效改善CHF患者的临床症状,增加LVEF,改善心功能。同时可有效治疗室性心动过速等恶性室性心律失常,预防心脏性猝死。     

慢性心力衰竭患者心脏再同步治疗疗效观察

Objective This study was designed to evaluate the clinical outcome of cardiac resynchro-nization therapy(CRT) during short and mid-long term follow-up. Methods Consecutive patients treated with CRT between 1999 and 2008 were registered. Clinical information was collected from baseline and last follow-up. Clinical information included survival, chnical cardiac function, echocardiography parameters and QRS wave width from surface ECG. Results Ninety-five patients who were treated with CRT successfully were included. These patients were divided into two groups: those with only short term follow-up and those with mid-long term follow-up. In the short term follow-up group,survival was 89.1% with follow-up of(18±10) month(median = 18 months). Survival was 66.6% in mid-long term group with follow-up of(57±17) months (median = 54 moths). While clinical cardiac function was significantly improved in both groups the intrinsic QRS wave width did not show significant change. Those patients' medical therapy for chronic heart failure has been changed dur-ing the period of follow-up. Conclusion CRT can improve clinical cardiac function in parts of patients with chronic heart failure and increased survival during mid-long term and short term follow-up. However, there re-mains a need for more sensitive indicators.     

慢性心力衰竭患者心脏再同步治疗疗效观察

Objective This study was designed to evaluate the clinical outcome of cardiac resynchro-nization therapy(CRT) during short and mid-long term follow-up. Methods Consecutive patients treated with CRT between 1999 and 2008 were registered. Clinical information was collected from baseline and last follow-up. Clinical information included survival, chnical cardiac function, echocardiography parameters and QRS wave width from surface ECG. Results Ninety-five patients who were treated with CRT successfully were included. These patients were divided into two groups: those with only short term follow-up and those with mid-long term follow-up. In the short term follow-up group,survival was 89.1% with follow-up of(18±10) month(median = 18 months). Survival was 66.6% in mid-long term group with follow-up of(57±17) months (median = 54 moths). While clinical cardiac function was significantly improved in both groups the intrinsic QRS wave width did not show significant change. Those patients' medical therapy for chronic heart failure has been changed dur-ing the period of follow-up. Conclusion CRT can improve clinical cardiac function in parts of patients with chronic heart failure and increased survival during mid-long term and short term follow-up. However, there re-mains a need for more sensitive indicators.     

慢性心力衰竭患者心脏再同步治疗疗效观察

目的随访慢性心力衰竭患者心脏再同步治疗（CRT）的临床疗效。方法入选1999年至2008年行CRT的慢性心力衰竭患者,收集这些患者基线和最后一次临床资料。采集数据包括临床心功能评估,心脏超声学指标和体表心电图QRS时限宽度。结果95例患者行CRT治疗,分为早期组和近期组。早期组随访时间（57±17）个月,随访生存率为66．6％;近期组随访时间（18±10）个月,生存率为89．1％。两组患者CRT治疗后心功能显著提高,但自身状态下体表心电图QRS时限宽度变化差异无统计学意义。随访中患者药物治疗变化明显。结论中长期和短期随访均证实CRT治疗在一部分慢性心力衰竭患者中能提高心功能,但缺乏预测疗效的敏感指标。     

慢性心力衰竭患者心脏再同步治疗疗效观察

Objective This study was designed to evaluate the clinical outcome of cardiac resynchro-nization therapy(CRT) during short and mid-long term follow-up. Methods Consecutive patients treated with CRT between 1999 and 2008 were registered. Clinical information was collected from baseline and last follow-up. Clinical information included survival, chnical cardiac function, echocardiography parameters and QRS wave width from surface ECG. Results Ninety-five patients who were treated with CRT successfully were included. These patients were divided into two groups: those with only short term follow-up and those with mid-long term follow-up. In the short term follow-up group,survival was 89.1% with follow-up of(18±10) month(median = 18 months). Survival was 66.6% in mid-long term group with follow-up of(57±17) months (median = 54 moths). While clinical cardiac function was significantly improved in both groups the intrinsic QRS wave width did not show significant change. Those patients' medical therapy for chronic heart failure has been changed dur-ing the period of follow-up. Conclusion CRT can improve clinical cardiac function in parts of patients with chronic heart failure and increased survival during mid-long term and short term follow-up. However, there re-mains a need for more sensitive indicators.     

慢性心力衰竭患者心脏再同步治疗疗效观察

Objective This study was designed to evaluate the clinical outcome of cardiac resynchro-nization therapy(CRT) during short and mid-long term follow-up. Methods Consecutive patients treated with CRT between 1999 and 2008 were registered. Clinical information was collected from baseline and last follow-up. Clinical information included survival, chnical cardiac function, echocardiography parameters and QRS wave width from surface ECG. Results Ninety-five patients who were treated with CRT successfully were included. These patients were divided into two groups: those with only short term follow-up and those with mid-long term follow-up. In the short term follow-up group,survival was 89.1% with follow-up of(18±10) month(median = 18 months). Survival was 66.6% in mid-long term group with follow-up of(57±17) months (median = 54 moths). While clinical cardiac function was significantly improved in both groups the intrinsic QRS wave width did not show significant change. Those patients' medical therapy for chronic heart failure has been changed dur-ing the period of follow-up. Conclusion CRT can improve clinical cardiac function in parts of patients with chronic heart failure and increased survival during mid-long term and short term follow-up. However, there re-mains a need for more sensitive indicators.     

心脏再同步治疗慢性心力衰竭的临床疗效

目的观察心脏再同步治疗慢性心力衰竭的临床疗效。方法36例慢性心力衰竭合并室内传导阻滞的患者行双心室再同步起搏治疗。全部患者均经冠状静脉窦植入左心室导线至心脏静脉。治疗后随访12个月,观察心功能,6min步行距离,QRS波宽度,心室间运动延迟,左心室收缩、舒张末内径,左心室射血分数,二尖瓣反流面积。结果31例治疗后心功能改善,有效率86．1％（31／36）。心功能从Ⅲ～Ⅳ级（纽约心脏协会心功能分级）改善为Ⅱ～Ⅲ级;6min步行距离从（362±153）m提高至（528_＋165）m,差异有统计学意义（P〈0．01）;QRS波从（164．74±33．76）ms缩短至（129．45±42．27）ms,差异有统计学意义（P〈0．01）;心室间运动延迟时间从（65．19±21．50）ms缩短至（33．25±13．62）ms,差异有统计学意义（P〈0．01）;左心室舒张末内径从（66．52±10．23）mm缩小至（60．63±9．97）mm（P〈0．05）,左心室收缩末内径从（55．73±10．62）mm缩小至（47．45±11．35）mm,差异有统计学意义（P〈0．01）;左心室射血分数从30．35％±4．69％提高至42．27％±8．40％,差异有统计学意义（P〈0．01）;二尖瓣反流面积从（7．52±3．62）cm2减少至（4．33±2．07）cm2,差异有统计学意义（P〈0．01）。结论心脏再同步治疗是治疗慢性心力衰竭的有效方法,能使心脏活动再同步化,改善心功能。